跳至主要内容
临床试验/NCT01208493
NCT01208493终止不适用

Dietary Protein in the Very-low-birth-weight Infant: Effects of the Level of Dietary Protein on Growth and Feeding Tolerance

Société des Produits Nestlé (SPN)8 个研究点 分布在 4 个国家目标入组 70 人开始时间: 2007年9月1日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
发起方
入组人数
70
试验地点
8
主要终点
comparison of weight gain between both study groups as a measure of safety

研究概览

简要总结

In this randomized study The investigators aim to compare the growth of very-low-birth-weight (VLBW) infants fed either a high protein or a standard protein preterm infant formula.

Babies will be fed the assigned formula between the time they achieve full enteral feeds and hospital discharge, for a minimum of 3 weeks. The weight gain (g/d) will be measured and compared between groups. Feeding tolerance, protein-energy status and body composition between the study groups will also be analysed.

After discharge, babies will be fed a post-discharge preterm infant formula (PDF) between hospital discharge and 3 m corrected age.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
1 Day 至 10 Weeks(Child)
性别
All
接受健康志愿者

入选标准

  • Gestational age <32 w, determined by maternal dates, fetal ultrasound, Dubowitz/Ballard examination or a combination thereof
  • Birth weight ≤1500 g
  • Tolerating an enteral intake of ≥100 ml/kg/d for ≥ 24 h
  • Subject is anticipated to receive the study formula for ≥ 3 consecutive weeks after FEF have been achieved
  • In infants fed human milk, formula is anticipated to provide 50% or more of total energy intake, calculated on a weekly basis and based on the assumption that human milk has an energy density of 67 kcal/dl
  • Written informed consent has been obtained from the legal representative

排除标准

  • Cardiac failure requiring fluid restriction with diuretic therapy for ≥ 3 consecutive days
  • Peri-/intra-ventricular haemorrhage (grade 3-4) determined using cranial ultrasonography
  • Renal disease: by symptoms (oliguria, anuria, proteinuria, hematuria) associated with an increased BUN and creatinine
  • Sepsis: defined by symptoms requiring antibiotic therapy and confirmed by a positive blood culture
  • Necrotizing Enterocolitis: defined by feeding intolerance associated with positive x-ray findings (pneumatosis intestinalis - Bell Stage 2; air in the biliary tract or free air in the peritoneum - Bell Stage 3)
  • Hepatic dysfunction: defined by jaundice (direct bilirubin >1.0 mg/dl) which is associated with one or more abnormal liver function tests (AST, ALT or GGT)
  • Lung disease, severe enough to require steroid therapy.
  • Small size for gestational age (SGA) - body weight ≤ 5th percentile for that gestational age.
  • Participation in another clinical trial that may affect outcomes of this study

结局指标

主要结局

comparison of weight gain between both study groups as a measure of safety

时间窗: 3 weeks

次要结局

  • comparison of feeding tolerance and metabolic status between study groups as a measure of safety(3 weeks)

研究者

发起方
Société des Produits Nestlé (SPN)
申办方类型
Industry
责任方
Sponsor

研究点 (8)

Loading locations...

相似试验

Dietary Protein in the Very-low-birth-weight Infant | 临床试验